OakChart

Citius Oncology Inc

CTORHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 1:12 PM ET

0.5598-0.0029 (-0.52%)
2026-11-11 19:13 CET
Market cap
52.32 USD m
Revenue, TTM
7.11 USD m
Net income, TTM
-46.06 USD m
Free cash flow, TTM
-19.71 USD m
EPS diluted, TTM
-0.47
P/E
-
Compare

Price

CTOR against its 20, 50 and 200-day averages
2050200miss
0.600.801.001.20518K1.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CTORclose 0.5620-day 0.6150-day 0.80200-day 0.810.5652w low

69.4% under the 52-week high of 1.83 on 1 Dec 2025. 52-week low 0.49 on 30 Mar 2026. Last 15 sessions, 47.8% high to low

Profile

CTOR
52-week range, 5% of the way up
0.491.83

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

IPODec 08, 2022
Beta3.54
ATR, 14d0.08
Rel volume0.30
Short float0.77%
Insider own71.95%
Inst own15.27%

Snapshot

6 groups

Valuation

Index-
Market Cap52.05M
Enterprise Value45.70M
Income-46.06M
Sales7.11M
Book/sh0.38
Cash/sh0.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPODec 08, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S7.32
P/B1.47
P/C3.14
P/FCF-
EV/EBITDA-
EV/Sales6.43
Quick Ratio0.34
Current Ratio0.73
Debt/Eq0.25
LT Debt/Eq0.25
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.47
EPS next Y-0.19
EPS next Q-0.07
EPS this Y-35.29%
EPS next Y58.70%
EPS next 5Y-
EPS past 3/5Y- -309.67%
Sales past 3/5Y- -
EPS Y/Y TTM-148.79%
Sales Y/Y TTM-
EPS Q/Q-10.27%
Sales Q/Q-
EarningsAug 14 AMC
EPS/Sales Surpr.-14.29% -40.25%

Ownership

Insider Own71.95%
Insider Trans0.00%
Inst Own15.27%
Inst Trans0.42%
ROA-45.20%
ROE-126.58%
ROIC-91.04%
Gross Margin28.92%
Oper. Margin-665.63%
Profit Margin-648.32%
SMA20-7.58%
SMA50-30.08%
SMA200-31.14%
Trades-

Technical

Shs Outstand105.76M
Shs Float26.09M
Short Float0.77%
Short Ratio1.78
Short Interest0.20M
52W High1.83 -69.41%
52W Low0.49 13.97%
Volatility11.11% 14.21%
ATR (14)0.08
RSI (14)38.13
Beta3.54
Rel Volume0.30
Avg Volume113.54K
Volume20,045

Performance

Perf Week2.34%
Perf Month-29.32%
Perf Quarter-32.29%
Perf Half Y-43.28%
Perf YTD-44.02%
Perf Year-59.14%
Perf 3Y-94.87%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price4.00
Prev Close0.56
Price0.56
Change %-0.52%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Sep 23, 2025UpgradeMMaxim GroupHold → Buy$6+971.8%
Nov 27, 2024InitiatedMMaxim GroupBuy$3+435.9%

Peers

Mkt cap
TickerCompanyMkt cap
ADCTAdc Therapeutics SA203.21M
SNGXSoligenix Inc7.48M
CHRSCoherus Oncology Inc91.22M
CLRBCellectar Biosciences Inc11.49M
ONCYOncolytics Biotech Inc48.34M
CRBPCorbus Pharmaceuticals Holdings Inc79.59M
GERNGeron Corp638.06M
INCYIncyte Corp24.88B
SNDXSyndax Pharmaceuticals Inc868.32M
IMNNImunon Inc4.32M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 66
  • Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire)
  • Citius Oncology's Positive Quality of Life Data for LYMPHIR (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe (PR Newswire)
  • Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 (PR Newswire)
  • Citius Pharmaceuticals to Participate in October 2026 Investor Conferences (PR Newswire)
  • Citius Pharmaceuticals to Participate in September 2026 Investor Conferences (PR Newswire)
  • Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum (InvestorsHub) -18.66%
  • Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire) +10.04%
  • Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
  • Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri (PR Newswire) +11.16%
  • Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment (PR Newswire) +18.94%
  • Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption (PR Newswire)
  • Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies (PR Newswire)
  • Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting (PR Newswire)
  • Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -13.95%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-14-0.080-0.070-0.0801.492.501
2026Q22026-05-15-0.270-0.010-0.2501.677.001
2026Q12026-02-13-0.060--0.0633.944.37-
2025Q42025-12-23-0.060-0.060-0.0620.000.001
2025Q32025-08-12-0.080-0.150-0.0750.000.001
2025Q22025-05-14-0.110--0.1080.005.74-
2025Q12025-02-14-0.090-0.060-0.0930.000.001
2024Q32024-12-27-0.080-0.080-0.0800.000.001
2024Q22024-08-28-0.070-0.0000.00--
2024Q4---0.060--0.001
2026Q4---0.070--3.291
2027Q1--0.000--14.271
2027Q2--0.040--20.931
2027Q3---0.040--28.551
2027Q4--0.100--31.401

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-0.310-0.290-0.3110.000.00
2025FY-0.340-0.330-0.3400.000.00
2026FY--0.460--10.39
2027FY--0.190--47.58
2028FY-0.260--125.93
2029FY-0.610--177.01
2030FY-0.690--196.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-271013.293.293.29
2026Q4S2026-10-211005.775.775.77
2026Q4S2026-08-171015.775.775.77
2026Q4S2026-08-071015.775.775.77
2026Q4S2026-08-011009.389.389.38
2026Q4S2026-05-191019.389.389.38
2026Q4S2026-05-181019.389.389.38
2026Q4S2026-05-0210017.0517.0517.05
2026Q4S2026-03-0610117.0517.0517.05
2026Q4S2026-03-0510117.0517.0517.05
2026Q4S2026-02-1710117.0517.0517.05
2026Q4S2026-02-1610117.0517.0517.05
2026Q4S2025-12-2410026.8626.8626.86
2026Q4S2025-12-0610026.8626.8626.86

Estimate history

EPS, annual-0.0010.0420.27-0.311-0.338-0.4737
Period20212022202320242025TTM
EPS, quarterly0--0.093-0.108-0.075-0.062-0.063-0.266-0.083
PeriodQ2 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000007.11
Period20212022202320242025TTM
Sales, quarterly0000003.9441.6671.494
PeriodQ2 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual8.149.0168.94171.55283.513105.759
Period20212022202320242025MRQ
Shares, quarterly--71.55271.55271.55283.51384.79892.981105.759
PeriodQ2 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue7.110.000.000.000.000.00
Cost of Goods Sold Incl. D&A5.050.000.000.000.000.00
Gross Profit2.050.000.000.000.000.00
Selling, General and Administrative Excl. Other49.3523.5220.571.010.14-
Research and Development3.976.424.93---
Other Operating Expense0.000.000.000.000.000.00
Operating Income-47.29-23.52-20.57-1.01-0.140.00
Interest Expense0.550.22-0.000.000.00
Unusual Expense0.000.000.000.00-0.030.00
Net Income Before Taxes-45.87-23.70-20.572.420.38-0.01
Income Taxes0.191.060.580.000.000.00
Consolidated Net Income-46.06-24.76-21.152.420.38-0.01
Net Income From Continuing Operations-46.06-24.76-21.152.420.38-0.01
Net Income-46.06-24.76-21.152.420.38-0.01
EPS (Recurring)-0.43-0.34-0.310.270.04-0.00
EPS (Basic, Before Extraordinaries)-0.47-0.34-0.310.270.04-0.00
EPS (Diluted)-0.47-0.34-0.310.270.04-0.00
EBITDA-43.85-23.52-20.57-1.01-0.140.00
Non-Operating Income (Expense)1.970.040.003.430.49-0.01
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense10.546.575.92---
Price To Earnings Ratio--5.6855.79--
Price To Sales Ratio9.87-----
Gross Margin28.92-----
Operating Margin-665.63-----
Net Margin-648.32-----
Shares Outstanding105.7683.5171.558.949.028.14
Market Capitalization52.3252.3218.9797.8190.8490.84

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.491.673.940.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.212.050.790.000.000.000.000.00
Gross Profit-0.72-0.383.150.000.000.000.000.00
Selling, General and Administrative Excl. Other8.0028.238.414.714.947.476.390.00
Research and Development0.221.081.591.080.943.141.26-
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.72-28.61-5.25-4.71-4.94-7.47-6.390.00
Interest Expense0.410.030.050.060.16--0.00
Unusual Expense0.000.000.000.000.000.000.00-
Net Income Before Taxes-9.03-26.84-5.27-4.73-5.11-7.47-6.390.00
Income Taxes-0.11-0.230.260.260.260.260.260.00
Consolidated Net Income-8.92-26.61-5.53-5.00-5.37-7.74-6.660.00
Net Income From Continuing Operations-8.92-26.61-5.53-5.00-5.37-7.74-6.660.00
Net Income-8.92-26.61-5.53-5.00-5.37-7.74-6.660.00
EPS (Recurring)-0.08-0.27-0.06-0.06-0.08-0.11-0.09-
EPS (Basic, Before Extraordinaries)-0.08-0.27-0.06-0.06-0.07-0.11-0.09-
EPS (Diluted)-0.08-0.27-0.06-0.06-0.07-0.11-0.09-
EBITDA-7.00-26.89-5.25-4.71-4.94-7.47-6.39-
Non-Operating Income (Expense)0.101.810.030.040.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.812.793.131.821.681.651.43-
Price To Earnings Ratio-------5.68
Price To Sales Ratio9.8711.0522.18-----
Gross Margin-48.09-22.9079.99-----
Operating Margin-583.54-1,716.17-133.17-----
Net Margin-597.40-1,595.98-140.31-----
Shares Outstanding105.7692.9884.8083.5171.5571.5571.55-
Market Capitalization52.3254.7284.80169.53311.2566.5482.0018.97

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments3.920.000.030.290.00
Short Term Receivables0.000.000.000.000.00
Inventories22.298.270.000.000.00
Other Current Assets1.332.700.030.090.00
Total Current Assets27.5410.970.060.380.00
Net Property, Plant & Equipment0.000.000.000.000.00
Total Investments and Advances0.000.0072.5767.810.00
Long-Term Note Receivable---0.000.03
Intangible Assets73.4073.400.000.000.00
Other Assets0.000.000.000.000.13
Total Assets100.9484.3772.6268.190.15
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.00
Accounts Payable13.233.710.000.000.00
Other Current Liabilities36.2628.992.050.030.14
Total Current Liabilities49.4932.702.050.030.14
Long Term Debt3.803.800.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities2.781.73---
Other Liabilities0.000.000.000.000.00
Total Liabilities56.0838.232.050.030.14
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.0072.5767.810.00
Common Equity44.8746.14-1.990.350.01
Total Shareholders Equity44.8746.1470.5868.160.01
Accumulated Minority Interest0.000.000.000.000.00
Total Equity44.8746.1470.5868.160.01
Total Liabilities & Stockholders Equity100.9484.3772.6268.190.15
Book Value Per Share0.540.64-0.220.040.00
Tangible Book Value Per Share-0.34-0.38-0.220.040.00
Price to Book Ratio1.47-3.04-90.295,551.915,551.91
Return on Assets-26.72-26.943.441.11-
Return on Equity-54.42-36.243.491.12-
Return on Invested Capital-50.88-42.353.430.56-67.93
Quick Ratio0.110.080.0311.850.00
Current Ratio0.560.340.0311.850.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-47.07-24.76-21.152.420.38-0.01
Other Funds (Non Cash)13.818.327.50-3.43-0.490.00
Funds from Operations-28.97-15.38-13.07-1.01-0.11-0.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital9.279.8913.200.410.060.01
Cash from Operating Activities-19.71-5.490.13-0.60-0.050.00
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.00-1.32-67.32-
Purchase of Investments0.000.000.00-1.32-67.32-
Sale Or Maturity of Investments0.000.000.000.000.00-
Other Uses-12.93-5.75-5.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-12.93-5.75-5.00-1.32-67.320.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock39.6615.170.000.0068.040.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock39.6615.170.000.0068.040.00
Proceedsfrom Stock Options29.7315.170.000.0068.040.00
Issuance or Reduction of Debt, Net9.830.003.800.000.000.00
Change in Long Term Debt9.830.003.800.000.000.00
Issuance of Long Term Debt9.830.003.800.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.001.071.66-0.380.00
Other Financing Activities Uses0.000.00-2.750.00-0.380.00
Cash from Financing Activities49.4815.174.871.6667.660.00
Net Change in Cash16.843.920.00-0.260.290.00
Free Cash Flow-19.71-5.490.13-0.60-0.05-
Preferred Dividends (Cash Flow)-0.000.00--0.00
Price to Free Cash Flow--748.37---
Deferred Taxes & Investment Tax Credit-1.060.580.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments16.562.637.303.920.000.00
Short Term Receivables0.691.084.050.000.000.00
Inventories22.6322.6622.6422.2917.2115.34
Other Current Assets2.833.053.161.331.102.70
Total Current Assets42.7129.4237.1527.5418.3118.04
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets69.3971.1172.8373.4073.4073.40
Other Assets0.000.170.000.000.000.00
Total Assets112.09100.70109.97100.9491.7191.44
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable7.328.8810.4513.238.677.68
Other Current Liabilities51.4749.9334.2636.2644.3242.06
Total Current Liabilities58.7958.8144.7149.4952.9949.74
Long Term Debt10.213.803.803.803.803.80
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities2.712.823.052.782.522.26
Other Liabilities0.000.000.000.000.000.00
Total Liabilities71.7165.4351.5656.0859.3155.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity40.3835.2758.4144.8732.4035.64
Total Shareholders Equity40.3835.2758.4144.8732.4035.64
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity40.3835.2758.4144.8732.4035.64
Total Liabilities & Stockholders Equity112.09100.70109.97100.9491.7191.44
Book Value Per Share0.380.380.690.540.450.50
Tangible Book Value Per Share-0.27-0.39-0.17-0.34-0.57-0.53
Price to Book Ratio1.470.901.864.488.731.61
Return on Assets-45.20-44.25-23.58---
Return on Equity-126.58-119.90-47.41---
Return on Invested Capital-17.64-68.11-8.90-10.27-14.83-19.61
Quick Ratio0.340.120.320.110.020.05
Current Ratio0.730.500.830.560.350.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-9.34-27.00-5.53-5.19-5.45-7.65
Depreciation1.77-----
Other Funds (Non Cash)3.873.044.532.362.152.06
Funds from Operations-3.81-21.87-0.74-2.56-3.04-5.32
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.9617.90-6.61-2.983.045.32
Cash from Operating Activities-2.85-3.97-7.35-5.530.000.00
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-2.08-0.66-4.40-5.790.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.08-0.66-4.40-5.790.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.30-0.0515.1315.280.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.30-0.0515.1315.280.000.00
Proceedsfrom Stock Options-0.63-0.0515.1315.280.000.00
Issuance or Reduction of Debt, Net9.830.000.000.000.000.00
Change in Long Term Debt9.830.000.000.000.000.00
Issuance of Long Term Debt9.830.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities19.12-0.0515.1315.280.000.00
Net Change in Cash14.20-4.683.373.950.000.00
Free Cash Flow-2.85-3.97-7.35-5.530.00-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.77%0.2M26.1M119.13K
2026-10-150.87%0.2M26.1M101.64K
2026-09-301.11%0.3M26.1M95.86K
2026-09-151.95%0.5M26.1M80.93K
2026-08-311.80%0.5M26.1M81.50K
2026-08-141.73%0.5M26.1M81.73K
2026-07-311.53%0.4M26.1M68.67K
2026-07-151.40%0.4M26.1M77.70K
2026-06-301.74%0.5M26.1M101.19K
2026-06-151.91%0.5M26.1M129.10K
2026-05-292.81%0.6M22.5M227.62K
2026-05-152.15%0.5M22.5M233.47K
2026-04-303.06%0.7M21.4M247.92K
2026-04-154.37%0.9M21.4M264.91K
2026-03-316.37%1.1M16.6M284.37K
2026-03-136.28%1.0M16.6M380.06K
2026-02-275.94%1.0M16.6M424.71K
2026-02-135.51%0.9M16.6M461.04K
2026-01-307.32%1.2M16.6M454.55K
2026-01-157.25%1.2M16.6M488.54K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-04SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-238-KCurrent report2026-10-19SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-08-26ARSAnnual report to security holders. 2025-09-30SEC
2026-08-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-29SEC
2026-08-143Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-14424B3SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-128-KCurrent report2026-08-07SEC
2026-08-05424B3SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-06-05EFFECTEffectiveness filing by commission orderSEC
2026-06-04SCHEDULE 13D/ASEC
2026-06-03CORRESPSEC
2026-06-03UPLOADUpload SubmissionSEC
2026-06-01424B3SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-29DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-05-29SEC
2026-05-29S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-22424B3SEC
2026-05-19PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-05-19SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-06424B3SEC
2026-05-068-KCurrent report2026-05-04SEC
2026-05-05424B3SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC9.36%
BANK OF AMERICA CORP /DE/4.12%
VANGUARD CAPITAL MANAGEMENT LLC0.59%
GEODE CAPITAL MANAGEMENT, LLC0.30%
VANGUARD FIDUCIARY TRUST CO0.13%
IFP Advisors, Inc0.12%
CITADEL ADVISORS LLC0.10%
NORTHERN TRUST CORP0.05%
STATE STREET CORP0.05%
Private Advisor Group, LLC0.03%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.40%
VANGUARD EXTENDED MARKET INDEX FUND0.19%
Fidelity Extended Market Index Fund0.10%
Fidelity Nasdaq Composite Index Fund0.06%
Fidelity Total Market Index Fund0.03%
Fidelity Series Total Market Index Fund0.03%

OakChart. CTOR. Cached 15 minutes.

Some panels did not load: insider.